In 2001, Gleevec was approved as a treatment for chronic myelogenous leukemia. It was a revelation for personalized medicine--with harrowing financial repercussions that persist today.
In 2001, Gleevec was approved as a treatment for chronic myelogenous leukemia. It was a revelation for personalized medicine--with harrowing financial repercussions that persist today.
Share this Article
Recommended